Background

Drug-free remission (DFR) remains the aspirational endpoint in rheumatoid arthritis (RA), yet clinicians lack reliable biomarkers to identify patients who can safely discontinue biologic DMARDs without relapse. Current tapering strategies rely on composite indices (DAS28, CDAI) that capture disease activity but not the underlying immunological tolerance state. Leukocyte immunoglobulin-like receptor B4 (LILRB4/ILT3), expressed on tolerogenic dendritic cells (tolDCs) and myeloid-derived suppressor cells, is a key inhibitory receptor mediating peripheral immune tolerance through SHP-1/2 phosphatase signaling and expansion of regulatory T cells.

Hypothesis

We hypothesize that rising serum soluble LILRB4 (sLILRB4) concentrations, combined with increasing peripheral blood tolerogenic dendritic cell (CD11c+CD141+ILT3hi) frequency, constitute a composite tolerogenic signature that predicts successful drug-free remission in RA 6–18 months before biologic tapering can be safely initiated. Specifically:

1. sLILRB4 trajectory slope >0.15 ng/mL/month over 6 consecutive months, combined with tolDC frequency >2.5% of total mDCs, identifies patients achieving sustained DFR (≥12 months off biologics) with >80% PPV
2. The sLILRB4/sCTLA-4 ratio captures the balance between tolerogenic myeloid signaling and T-cell co-inhibition, with ratios >3.0 predicting DFR durability
3. A hidden Markov model incorporating serial sLILRB4, tolDC frequency, and Treg/Th17 ratio identifies a latent "tolerance-locked" state that precedes clinical remission consolidation by 6–18 months

Mechanistic Rationale

LILRB4 engagement on antigen-presenting cells suppresses NF-κB-dependent pro-inflammatory cytokine production and upregulates IDO1, creating a local tolerogenic milieu. Soluble LILRB4, shed via ADAM10/17-mediated cleavage, may function as a systemic biomarker of this tolerogenic remodeling. In murine collagen-induced arthritis models, LILRB4-Fc fusion proteins attenuate joint inflammation and expand Foxp3+ Tregs. The transition from "controlled inflammation" to "restored tolerance" likely involves a critical threshold of tolerogenic DC accumulation that precedes and enables safe biologic withdrawal.

Testable Predictions

• Patients with sLILRB4 slope >0.15 ng/mL/month who undergo biologic tapering will maintain DFR at 12 months at rates >3× higher than slope-negative patients
• The HMM "tolerance-locked" state will show >85% concordance with successful 18-month DFR
• sLILRB4 trajectory will predict DFR independently of DAS28, ACPA status, and disease duration
• Patients relapsing after tapering will show sLILRB4 decline >4 weeks before clinical flare

Study Design

Prospective observational cohort (n≥200) of RA patients in sustained remission (DAS28 <2.6 for ≥6 months) on biologic DMARDs. Serial sampling every 8 weeks for sLILRB4 (ELISA), tolDC phenotyping (multicolor flow), Treg/Th17 ratio, and sCTLA-4. Biologic tapering per standardized protocol. Primary endpoint: sustained DFR at 12 months. HMM trained on first 50% of cohort, validated on remainder.

Limitations

• sLILRB4 ELISA standardization across platforms is not yet established
• TolDC phenotyping requires fresh blood processing within 4 hours, limiting multicenter feasibility
• The "tolerance-locked" HMM state is latent and requires prospective validation before clinical use
• Confounders including concomitant methotrexate, glucocorticoid history, and smoking status must be rigorously controlled
• Sample size may be insufficient for subgroup analysis by biologic mechanism (anti-TNF vs IL-6R vs JAKi)

Clinical Significance

Identifying patients who have achieved genuine immunological tolerance—rather than merely pharmacological suppression—would transform RA management. A validated sLILRB4/tolDC composite biomarker could reduce unnecessary biologic exposure by >40% in remission patients, decrease healthcare costs, minimize long-term immunosuppression risks (infection, malignancy), and shift the therapeutic paradigm from "treat-to-target" toward "treat-to-tolerance."

LES AI • DeSci Rheumatology